On Glassdoor, Amarex is listed as doing 5-25 million in revenue. Very big range but I would guess they likely have less than 5 million in funds to pay in arbitration settlement. I don’t think Cytodyn is really thinking this is going to fund much. Amarex will declare bankruptcy and Cytodyn will get what is available. I doubt NSF will be on the hook, Amarex is a separate company doing its own business. It is not a shell company formed to isolate nsf from these kind of problems. Unless nsf was actively involved with the CRO process for Cytodyn, I doubt they have any risk. Just because the nsf ceo was contacted and he said he would look into things does not make nsf involved with Amarex’s issues.

It is still clear that Cytodyn needs a partner to advance indications through trials. This is the future of the company, not an arbitration windfall that will be less than a few million.

Also, SA is charging Cytodyn legal fees, it is in the quartet reports. They are just lawyers doing their job.